Methods and rationale of the DISCOVER CKD global observational study.
chronic kidney disease
methods and rationale
patient-reported outcomes
quality of life
real-world evidence
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
01
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Real-world data for patients with chronic kidney disease (CKD), specifically pertaining to clinical management, metabolic control, treatment patterns, quality of life (QoL) and dietary patterns, are limited. Understanding these gaps using real-world, routine care data will improve our understanding of the challenges and consequences faced by patients with CKD, and will facilitate the long-term goal of improving their management and prognosis. DISCOVER CKD follows an enriched hybrid study design, with both retrospective and prospective patient cohorts, integrating primary and secondary data from patients with CKD from China, Italy, Japan, Sweden, the UK and the USA. Data will be prospectively captured over a 3-year period from >1000 patients with CKD who will be followed up for at least 1 year via electronic case report form entry during routine clinical visits and also via a mobile/tablet-based application, enabling the capture of patient-reported outcomes (PROs). In-depth interviews will be conducted in a subset of ∼100 patients. Separately, secondary data will be retrospectively captured from >2 000 000 patients with CKD, extracted from existing datasets and registries. The DISCOVER CKD program captures and will report on patient demographics, biomarker and laboratory measurements, medical histories, clinical outcomes, healthcare resource utilization, medications, dietary patterns, physical activity and PROs (including QoL and qualitative interviews). The DISCOVER CKD program will provide contemporary real-world insight to inform clinical practice and improve our understanding of the epidemiology and clinical and economic burden of CKD, as well as determinants of clinical outcomes and PROs from a range of geographical regions in a real-world CKD setting.
Sections du résumé
BACKGROUND
BACKGROUND
Real-world data for patients with chronic kidney disease (CKD), specifically pertaining to clinical management, metabolic control, treatment patterns, quality of life (QoL) and dietary patterns, are limited. Understanding these gaps using real-world, routine care data will improve our understanding of the challenges and consequences faced by patients with CKD, and will facilitate the long-term goal of improving their management and prognosis.
METHODS
METHODS
DISCOVER CKD follows an enriched hybrid study design, with both retrospective and prospective patient cohorts, integrating primary and secondary data from patients with CKD from China, Italy, Japan, Sweden, the UK and the USA. Data will be prospectively captured over a 3-year period from >1000 patients with CKD who will be followed up for at least 1 year via electronic case report form entry during routine clinical visits and also via a mobile/tablet-based application, enabling the capture of patient-reported outcomes (PROs). In-depth interviews will be conducted in a subset of ∼100 patients. Separately, secondary data will be retrospectively captured from >2 000 000 patients with CKD, extracted from existing datasets and registries.
RESULTS
RESULTS
The DISCOVER CKD program captures and will report on patient demographics, biomarker and laboratory measurements, medical histories, clinical outcomes, healthcare resource utilization, medications, dietary patterns, physical activity and PROs (including QoL and qualitative interviews).
CONCLUSIONS
CONCLUSIONS
The DISCOVER CKD program will provide contemporary real-world insight to inform clinical practice and improve our understanding of the epidemiology and clinical and economic burden of CKD, as well as determinants of clinical outcomes and PROs from a range of geographical regions in a real-world CKD setting.
Identifiants
pubmed: 34249352
doi: 10.1093/ckj/sfab046
pii: sfab046
pmc: PMC8264307
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1570-1578Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Clin Kidney J. 2020 Jun 22;13(4):693-709
pubmed: 32897277
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):7-15
pubmed: 15486868
Kidney Int Suppl (2011). 2012 Dec;2(5):357-362
pubmed: 25018962
Hypertens Res. 2008 Jun;31(6):1101-7
pubmed: 18716357
Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S22-38
pubmed: 24461727
Prev Chronic Dis. 2006 Oct;3(4):A118
pubmed: 16978493
JRSM Cardiovasc Dis. 2016 Nov 03;5:2048004016677687
pubmed: 27867500
JAMA. 2019 Oct 1;322(13):1294-1304
pubmed: 31573641
Bone. 2019 Dec;129:115058
pubmed: 31493530
Clin Kidney J. 2019 Aug 03;13(4):613-624
pubmed: 32905241
Int J Nephrol Renovasc Dis. 2019 Dec 24;12:263-276
pubmed: 31920363
Front Med (Lausanne). 2018 Jan 15;4:254
pubmed: 29379784
Arthritis Res Ther. 2010;12(5):R177
pubmed: 20860837
Front Pediatr. 2018 Jun 20;6:161
pubmed: 29974043
Kidney Int. 2011 Jun;79(12):1341-52
pubmed: 21307840
Perit Dial Int. 2016 May-Jun;36(3):297-307
pubmed: 26526049
J Nephrol. 2019 Aug;32(4):499-516
pubmed: 31119681
Am J Kidney Dis. 2016 Sep;68(3):402-13
pubmed: 27113505
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Kidney Int. 2019 Oct;96(4):983-994
pubmed: 31358344
JCO Clin Cancer Inform. 2018 Dec;2:1-10
pubmed: 30652541
Clin Kidney J. 2016 Feb;9(1):119-27
pubmed: 26798472
Nephrol Dial Transplant. 2015 Oct;30(10):1605-14
pubmed: 25982327
Front Pharmacol. 2019 Aug 16;10:932
pubmed: 31474869
Int J Nephrol Renovasc Dis. 2017 Feb 07;10:35-45
pubmed: 28223836
BMC Nephrol. 2014 May 19;15:80
pubmed: 24884708
Kidney Int. 2014 Sep;86(3):497-505
pubmed: 24694985
Lancet. 2020 Feb 29;395(10225):662-664
pubmed: 32061314
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
J Nephropathol. 2014 Jul;3(3):99-104
pubmed: 25093157
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Kidney Int Suppl. 2008 Apr;(108):S145-51
pubmed: 18379538
Circulation. 2019 Apr 16;139(16):e840-e878
pubmed: 30852913
Kidney Int. 2019 Nov;96(5):1217-1233
pubmed: 31570197
BMC Nephrol. 2013 Jun 11;14:121
pubmed: 23758910
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Kidney Int. 2020 Oct;98(4S):S1-S115
pubmed: 32998798
Lancet. 2017 Oct 21;390(10105):1888-1917
pubmed: 28434650
Sci Rep. 2020 Apr 30;10(1):7351
pubmed: 32355258
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Kidney Blood Press Res. 2018;43(3):959-969
pubmed: 29895022
Ren Fail. 2020 Nov;42(1):733-739
pubmed: 32718215
PLoS One. 2016 Jul 21;11(7):e0159335
pubmed: 27442587
J Med Internet Res. 2020 Jul 15;22(7):e18548
pubmed: 32673242
Kidney Int. 2020 Jun;97(6):1117-1129
pubmed: 32409237
J Pharm Health Care Sci. 2015 May 01;1:16
pubmed: 26819727